Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Anti-MAG Polyneuropathy
NCT00259974Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2006
- Primary completion
- Jan 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in anti-myelin-associated glycoprotein neuropathy, sponsored by Assistance publique - Hôpitaux de Paris. Started Apr 2006; status: completed.
02
Drugs
rituximab
03
Conditions
anti-myelin-associated glycoprotein neuropathy
Beyond the preview
Go deeper on NCT00259974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00259974.